Who
Mark Stanley Berger
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Genprex; Chief Medical Officer, Actinium Pharmaceuticals, Inc. (Delaware).
In numbers
- Trades disclosed
- 19
- Buys
- 1
- Sells
- 0
- Bought
- $5,550
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 15 Jun 2017
- Last trade
- 27 Feb 2026
- Last filed
- 27 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 Feb 2026filed 27 Feb 2026 | GNPX GenprexBiotechnology | SEC FORM 4 Code F | $14K7,168 at $2.00 | filing |
| 27 Feb 2026filed 27 Feb 2026 | GNPX GenprexBiotechnology | SEC FORM 4 Code F | $14K7,168 at $2.00 | filing |
| 22 Dec 2025filed 23 Dec 2025 | GNPX GenprexBiotechnology | SEC FORM 4 Code A | —28,500 at $0.00 | filing |
| 30 Jun 2025filed 1 Jul 2025 | GNPX GenprexBiotechnology | SEC FORM 4 Code F | $1,0354,500 at $0.23 | filing |
| 18 Feb 2025filed 19 Feb 2025 | GNPX GenprexBiotechnology | SEC FORM 4 Code F | $240585 at $0.41 | filing |
| 5 Dec 2024filed 6 Dec 2024 | GNPX GenprexBiotechnology | SEC FORM 4 Code A | —18,250 at $0.00 | filing |
| 18 Feb 2024filed 21 Feb 2024 | GNPX GenprexBiotechnology | SEC FORM 4 Code F | $5,8041,319 at $4.40 | filing |
| 18 Feb 2023filed 22 Feb 2023 | GNPX GenprexBiotechnology | SEC FORM 4 Code A | —245,000 at $0.00 | filing |
| 4 Feb 2022filed 8 Feb 2022 | GNPX Genprexoption or derivative · Biotechnology | SEC FORM 4 Code A | —98,750 at $0.00 | filing |
| 27 Sep 2021filed 28 Sep 2021 | GNPX Genprexoption or derivative · Biotechnology | SEC FORM 4 Code A | —550,000 at $0.00 | filing |
| 1 Sep 2021filed 3 Sep 2021 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code A | —67,164 at $0.00 | filing |
| 12 Aug 2020filed 14 Aug 2020 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code A | —46,667 at $0.00 | filing |
| 12 Jul 2019filed 16 Jul 2019 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code A | $92K400,000 at $0.23 | filing |
| 5 Mar 2019filed 7 Mar 2019 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)Biotechnology | SEC FORM 4 Code X | $2,1003,500 at $0.60 | filing |
| 13 Jul 2018filed 17 Jul 2018 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code A | $195K250,000 at $0.78 | filing |
| 6 Mar 2018filed 19 Mar 2018 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)Biotechnology | SEC FORM 4 Code J | $7,00014,000 at $0.50 | filing |
| 6 Mar 2018filed 19 Mar 2018 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code J | $1,7503,500 at $0.50 | filing |
| 6 Mar 2018filed 19 Mar 2018 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code J | $5,25010,500 at $0.50 | filing |
| 15 Jun 2017filed 15 Jun 2017 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)Biotechnology | SEC FORM 4 Bought | $5,5505,000 at $1.11 | filing |
News
No headline names them, or the companies they trade most, lately.